RecruitingPhase 4NCT04478838

"Extended" (Alternate Day) Antipsychotic Dosing

"Re-examining Maintenance Antipsychotic Treatment in Schizophrenia: "Extended" Antipsychotic Dosing"


Sponsor

Centre for Addiction and Mental Health

Enrollment

120 participants

Start Date

Jun 6, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The study wishes to examine whether "extended" antipsychotic treatment, in this case, antipsychotic treatment every other day, is as effective as daily treatment. It is also evaluating whether there may be differences in terms of side effects. Participants will be randomly assigned to either the treatment as usual group (i.e., taking antipsychotic daily) or the extended dosing group (i.e., taking antipsychotic one day on, one day off). That means, like flipping a coin, there is a 50/50 chance that participants will continue on daily dosing of your antipsychotic or have it switched to every other day dosing. This study will last for 1 year. Participants will be evaluated at the beginning and every two weeks during the first 6 months, with visits once every 4 weeks for the final 6 months. In total, participants will make 22 visits over 52 weeks to the investigator's office. The investigators hypothesize that with ED, there will be no change in symptom severity but improvement in the frequency and severity of side effects, wellbeing, and functioning.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether taking antipsychotic medication every other day (instead of every day) is safe and effective for people with schizophrenia or related psychotic disorders who are currently stable on their medication. This approach could reduce side effects and improve quality of life. **You may be eligible if...** - You are 18 or older and have a diagnosis of schizophrenia or another psychotic disorder - You are currently stable and taking risperidone, olanzapine, or paliperidone as a single oral medication - You are an outpatient (not currently hospitalized) - You can communicate in English and provide informed consent **You may NOT be eligible if...** - You are currently pregnant or unwilling to use contraception - You are not stable on your current medication - You are taking more than one antipsychotic medication - You have significant health conditions that would make dose changes unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRisperidone

0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg Tablets

DRUGOlanzapine

2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg Tablets

DRUGpaliperidone

3 mg, 6 mg, 9 mg Tablets


Locations(1)

Centre for Addiction and Mental Health

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04478838


Related Trials